Search for: "BRISTOL-MYERS SQUIBB COMPANY" Results 201 - 220 of 469
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
31 Jan 2015, 8:47 pm by Mark Summerfield
The issue of what, exactly, is ‘implicitly’ disclosed in a prior art reference arises in a decision of a full bench of the Federal Court issued on 23 January 2015 (Bristol-Myers Squibb Company v Apotex Pty Ltd [2015] FCAFC 2) in an appeal relating to a long-running dispute over the validity of a patent covering the antipsychotic drug aripiprazole. [read post]
21 Jan 2015, 3:02 pm
Its corporate talking heads (Bristol-Myers Squibb and Pfizer) said such spending helps ensure that providers understand its appropriate use, and how important it is “to have a speaker program that adequately provides robust education to these physicians. [read post]
24 Dec 2014, 5:00 am
”  Being liable for purported defects in a competing product means, of course, that the costs of such liability can only be recouped by charging ones own customers more for other, non-defective products, but there are more plaintiff lawyers than innovator drug companies in Alabama. [read post]
20 Dec 2014, 10:53 am by Tom Lamb
That is, Bristol-Myers Squibb and Pfizer do not state in these advertisements that there is no FDA-approved antidote for Eliquis as regards its blood-thinner effect at this time. [read post]
18 Jul 2014, 11:55 am
This post is only from the Reed Smith (more properly, the non-Dechert) side of the blog.One hundred what, you say? [read post]
19 Jun 2014, 8:11 am
TAP Pharmaceuticals (Bristol Myers Squibb Appeal), No. 85 MAP 2011, slip op. [read post]
12 Jun 2014, 10:41 am by Jason Rantanen
Bristol-Myers Squibb Company v. [read post]
15 May 2014, 11:40 am
I accept that, for the reasons explained by Jacob J in Bristol-Myers Squibb and Lord Hoffmann in Kirin-Amgen, courts should be cautious before relying upon prosecution history as an aid to construction. [read post]
1 May 2014, 1:29 am by Ben Vernia
The government had investigated and settled other allegations, but the settlement specifically reserved the relator’s right to pursue certain off-label promotion and kickback charges against Bristol-Myers Squibb for three drugs. [read post]
3 Apr 2014, 9:55 pm by Patent Docs
Bristol-Myers Squibb Company v. [read post]